サンプル依頼リスト カート
  • English
  • Korean
表紙：一般的ないぼ治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1374794

一般的ないぼ治療の世界市場-2023年～2030年

Global Common Warts Treatment Market -2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
一般的ないぼ治療の世界市場-2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

尋常性疣贅（じんじょうせいゆうぜい）は、ヒトパピローマウイルス（HPV）によって生じる良性の皮膚増殖症です。多くの場合、小さく、盛り上がり、ざらざらした、カリフラワーのような外見をしています。尋常性疣贅は体のどの部位にもできる可能性があるが、通常は手、指、爪の周りにできることが多いです。

世界の尋常性疣贅治療市場は近年大きく成長しており、今後も上昇傾向が続くと予測されています。この市場は、免疫療法や、自己治療用の使いやすい凍結療法キットが入手可能になったことによる凍結療法への導入の増加など、いくつかの重要な動向の影響を受け、変革期を迎えています。

市場促進要因：市場抑制要因

臓器移植の増加

臓器移植の増加に伴い、尋常性疣贅治療市場は成長すると予想されます。臓器移植を受けた患者は免疫不全状態にあるため、ヒトパピローマウイルス（HPV）による尋常性疣贅などの疣贅を発症しやすいです。移植後、皮膚腫瘍に罹患する可能性は免疫不全集団よりもかなり高いです。いぼの有病率は免疫抑制期間とともに増加し、移植後4～5年以上経過した患者では50～90％に達します。

いぼの発生は、使用した免疫抑制剤や移植の間隔にも影響されます。さらに、皮膚尋常性疣贅（尋常性疣贅）は腎移植後の一般的な合併症です。2023年にBaishideng Publishing Groupに発表された報告によると、KTを受けた60人の小児および青年の研究では、いぼの発生率は28％であり、腎移植後時間が経つにつれて有病率が増加しています。上記の要因の結果、市場は予測期間を通じて成長すると予想されます。

市場力学：抑制要因

尋常性疣贅に関する化粧品とスティグマへの懸念は、尋常性疣贅のような目に見える皮膚疾患に関連する社会的スティグマから生じるものであり、これは人に不快感や自意識を抱かせる可能性があります。このようなスティグマは、その症状に対する誤解によって引き起こされることもあり、医療を受ける意欲を失わせることもあります。

さらに、特にいぼが目立つ場所にある場合、凍結療法や外科的切除などの治療による傷跡や皮膚の損傷に対する懸念も、人々が助けを求めることを妨げる可能性があります。こうした心理的・美容的要因に加え、痛みを伴う治療法に対する不安が、一般的ないぼの治療を妨げる可能性があるため、予測期間中の市場は抑制されることになります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 臓器移植の増加
    • 抑制要因
      • 化粧品と汚名への懸念
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMI意見

第6章 COVID-19分析

第7章 治療タイプ別

  • 薬物療法
    • サリチル酸
    • 硝酸銀
    • グルタルアルデヒド
    • ブレオマイシン
    • イミキモド
    • アミノレブリン酸
  • 凍結療法
  • レーザー療法
  • 外科的除去
  • 免疫療法

第8章 年齢層別

  • 小児
  • 成人

第9章 販売チャネル別

  • エンドユーザー
    • 病院
    • 皮膚科クリニック
    • 在宅医療
  • 販売チャネル
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Prestige Consumer Healthcare Inc.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • STADA Arzneimittel AG
  • Bausch Health Companies Inc.
  • Pfizer Inc.
  • Verrica Pharmaceuticals
  • GlaxoSmithKline plc
  • Taro pharmaceutical Industries Ltd.
  • Orgenesis biotech company
  • Teva pharmaceutical industries Ltd.
  • Novan Inc.

第13章 付録

目次
Product Code: PH7310

Overview

Common warts, commonly known as verruca vulgaris, are benign skin growths that are caused by the human papillomavirus (HPV). They are often tiny, raised, rough, and cauliflower-like in appearance. Common warts can appear on any area of the body, although they are most usually found on the hands, fingers, and around the nails.

The global common warts treatment market has grown significantly in recent years and is projected to continue on its upward trend. The market is undergoing a transformational period, influenced by several significant trends such increasing adoption towards immunotherapy and cryotherapy due to its availability of easy-to-use cryotherapy kits for self-treatment.

Market Dynamics: Drivers and Restraints

The increasing number of organ transplant

The market for common warts treatment is expected to grow as the number of organ transplants increases. Owing to their immunocompromised state, organ transplant recipients are more susceptible to developing warts such as common warts caused by human papillomavirus (HPV). After transplantation, the chance of acquiring cutaneous tumors is substantially higher than in the immunocompetent population. The prevalence of warts increases with the duration of immunosuppression, reaching 50-90% in patients more than 4-5 years after transplantation.

The development of warts is also affected by the immunosuppressant used and the time interval between transplants. Furthermore, cutaneous common warts (verruca vulgaris) are a common complication following kidney transplantation. According to a report published in Baishideng Publishing Group in 2023, the incidence of warts was 28% in a study of 60 children and adolescents with KT, with increasing prevalence with time after kidney transplantation. As a result of the factors listed above, the market is expected to grow throughout the forecast period.

Market Dynamics: Restraint

Cosmetics and stigma concerns about common warts arise from the social stigma associated with visible skin disorders such as common warts, which may cause persons uncomfortable or self-conscious. This stigma is sometimes caused by misconceptions about the condition and might discourage people from seeking medical treatment.

Moreover, concerns about scars or skin damage from treatments like cryotherapy or surgical removal can also prevent people from seeking help, especially if the warts are in prominent areas. These psychological and cosmetic factors, along with anxiety about painful treatment methods, can prevent people from treating common warts thereby restraining the market over the forecast period.

Segment Analysis

The global common warts treatment market is segmented based on treament type, age group, sales channel and region.

The drug therapy segment accounted for approximately 32.2% of the common warts treatment market share

The drug therapy segment is expected to dominate the global common warts treatment market accounted for 54.2% market share, due to its accessibility, convenience, and non-invasive nature, which makes it a popular choice, particularly for mild to moderate cases. Drug therapies, which include topical creams, solutions, and gels containing active ingredients such as salicylic acid and Imiquimod, offer patients an effective way of treating common warts while causing little impact on their everyday lives.

Furthermore, salicyclic acid solutions is most commonly used drug therapy for common warts, as this solution forms a thin layer over the wart. It works as keratolytic therapy that works by chemically debriding the wart of excess keratin and inducing an inflammatory response. Moreover, it is readily available without prescription too in pharmacies. This solution has shown very effective for treating this warts. For instance, according to National Library of Medicine 2022 report study, states that about 39 out of 100 people who used salicylic acid no longer had any warts in compare to people that received placebo. Thus, due to better efficacy and effectiveness the segment is expected to dominate over the forecast period.

Geographical Penetration

North America accounted for approximately 37.4% of the market share in 2022

North America is estimated to hold about 37.4% of the total market share throughout the forecast period, owing to the increasing number of prevalence of HPV and associated cancer with this HPV infection, growing awareness about the warts and launch of new products will drive this region further during the forecast period.

For instance, according to Centers for Disease Control and Prevention 2023 article, In the U.S., approximately 46,711 new cancer cases are diagnosed each year in areas of the body that are usually associated with human papillomavirus (HPV). There are 25,689 female cases and 21,022 male cases among these.

Moreover, HPV is responsible for around 37,000 of these cancer cases. Cervical cancer is the most common HPV-linked disease in women, whereas oropharyngeal cancers, which include malignancies in the throat's posterior region, including the base of the tongue and tonsils, are the most common in men. Thus, owing to above factors the region is expected to grow over the forecast period.

COVID-19 Impact Analysis

There have been multiple cases of COVID-19 and COVID-19 vaccinations causing warts. One report specifics the elimination of long-standing treatment-resistant warts in a transplant patient during COVID-19. The patient's hypoxic state as a result of COVID-19 may have an effect on wart regression. Another study proposes that SARS-CoV-2 infection may have initiated viral clearance by generating a delayed hypersensitivity reaction, as seen in the treatment of recalcitrant warts with intralesional MMR and BCG vaccine, PPD, and trichophyton antigens.

A third study reports the disappearance of common viral warts following the administration of the ChAdOx1S COVID-19 vaccination. Finally, two incidences of wart regression were identified during COVID-19 treatment, according to a report.

Competitive Landscape

The major global players in the common warts treatment market include: Prestige Consumer Healthcare Inc., STADA Arzneimittel AG, Bausch Health Companies Inc., Pfizer Inc., Verrica Pharmaceuticals, GlaxoSmithKline plc, Taro pharmaceutical Industries Ltd., Orgenesis biotech company, Teva pharmaceutical industries Ltd., Novan Inc. and among others.

Key Developments

  • On June 14, 2023, Vial, a worldwide technology-driven CRO that provides next-generation clinical trial administration services, has partnered up with Nielsen BioSciences, Inc. (Nielsen), a privately-held biopharmaceutical company based in San Diego, CA, to investigate the safety and efficacy of CANDIN for the treatment of common warts. Nielsen focuses on the development and commercialization of biological products that have broad applications in cell-mediated immune responses.
  • On April 10, 2023, KinoPharma started a Phase II clinical trial of a medication candidate to treat cutaneous warts, a human papillomavirus (HPV) infection, in collaboration with IWAKI SEIYAKU.

Why Purchase the Report?

  • To visualize the global common warts treatment market segmentation based on treatment type, age group, sales channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of common warts treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping is available in excel consisting of key products of all the major players.

The global common warts treatment market report would provide approximately 61 tables, 57 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by Age Group
  • 3.3. Snippet by Sales Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing number of organ transplant
    • 4.1.2. Restraints
      • 4.1.2.1. Cosmetics and stigma concerns
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Drug Therapy*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
      • 7.2.2.1. Salicylic Acid
      • 7.2.2.2. Silver Nitrate
      • 7.2.2.3. Glutaraldehyde
      • 7.2.2.4. Bleomycin
      • 7.2.2.5. Imiquimod
      • 7.2.2.6. Aminolevulinic Acid
  • 7.3. Cryotherapy
  • 7.4. Laser Therapy
  • 7.5. Surgical Removal
  • 7.6. Immunotherapy

8. By Age Group

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 8.1.2. Market Attractiveness Index, By Age Group
  • 8.2. Pediatric*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Adult

9. By Sales Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 9.1.2. Market Attractiveness Index, By Sales Channel
  • 9.2. End User*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
      • 9.2.2.1. Hospitals
      • 9.2.2.2. Dermatology Clinics
      • 9.2.2.3. Homecare Settings
  • 9.3. Distribution Channel
      • 9.3.1.1. Hospitals Pharmacies
      • 9.3.1.2. Retail Pharmacies
      • 9.3.1.3. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Prestige Consumer Healthcare Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. STADA Arzneimittel AG
  • 12.3. Bausch Health Companies Inc.
  • 12.4. Pfizer Inc.
  • 12.5. Verrica Pharmaceuticals
  • 12.6. GlaxoSmithKline plc
  • 12.7. Taro pharmaceutical Industries Ltd.
  • 12.8. Orgenesis biotech company
  • 12.9. Teva pharmaceutical industries Ltd.
  • 12.10. Novan Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us